Indivior PLC
LSE:INDV
Indivior PLC
LSE:INDV
Price:
1 432 GBX
0.35%
Market Closed
Updated:
May 11, 2024
Indivior PLC
Operating Income
|
Indivior PLC
Operating Income Peer Comparison
Comparables:
GSK
AZN
VRNA
HIK
DPH
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Indivior PLC
LSE:INDV
|
Operating Income
$257m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Operating Income
£7.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Operating Income
$8.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Operating Income
-$67.6m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Operating Income
$622m
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Operating Income
£24.9m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
3%
|
See Also
What is Indivior PLC's Operating Income?
Operating Income
257m
USD
257m
USD
Based on the financial report for Mar 31, 2024, Indivior PLC's Operating Income amounts to 257m USD.
What is Indivior PLC's Operating Income growth rate?
Operating Income CAGR 5Y
-5%
-5%
Over the last year, the Operating Income growth was 14%. The average annual Operating Income growth rates for Indivior PLC have been 20% over the past three years , -5% over the past five years .
You don't have any saved screeners yet
